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ABSTRACT
In the face of increasing resistance to currently available antibiotics, there is a continued interest in the
development of new drugs to treat Gram-positive infections. One such agent is the cyclic lipopeptide
daptomycin—licensed in the USA for treatment of Gram-positive complicated skin and skin structure
infections (cSSSIs) in 2003 and currently awaiting European approval for a similar indication (complicated
skin and soft tissue infections). Daptomycin exerts its rapid bactericidal effect through insertion into and
subsequent depolarisation of the bacterial cell membrane, a mode of action unlike that of any other
available antibiotic. This novel mechanism of action makes the development of cross-resistance between
daptomycin and other antibiotic classes unlikely. Daptomycin is highly active in vitro against a range of
Gram-positive pathogens, including both susceptible and multidrug-resistant staphylococci and
enterococci. Bactericidal activity has also been demonstrated against both growing and stationary-phase
organisms, suggesting potential utility in the treatment of deep-seated infections. Two pivotal clinical
studies comparing daptomycin 4 mg ⁄kg per day intravenously with vancomycin or oxacillin-class
antibiotics demonstrated the efficacy of daptomycin for treatment of cSSSIs. Daptomycin was well
tolerated, with most adverse events considered to be unrelated to study medication, of mild-to-moderate
intensity, and with a frequency and distribution similar to those associated with comparator antibiotics.
The favourable clinical profile and low potential for development of resistance combine to make
daptomycin a promising alternative to current agents for treatment of Gram-positive bacterial infections.
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INTRODUCTION
The number of cases of hospital-onset Staphylo-
coccus aureus and enterococcal infections that are
resistant to antimicrobial agents has increased
significantly over the past three decades [1–3].
Moreover, methicillin-resistant S. aureus (MRSA)
is fast becoming a community-based as well as a
hospital-based problem [4–8]. The glycopeptide
vancomycin has been the principal drug of choice
for the treatment of MRSA infection for many
years. However, over-reliance on vancomycin has
resulted in the recent development of the first
cases of resistance [9–12], and therefore its con-
tinued clinical value may be expected to become
self-limiting. Other agents currently used to treat
MRSA infection include the glycopeptide teicopl-
anin, the streptogramin combination quinupris-
tin–dalfopristin, and the oxazolidinone linezolid.
The clinical value of each of these treatments is,
however, limited by one or more factors, inclu-
ding antibacterial spectrum of activity, complex
administration, side-effect profile and the increas-
ing emergence of resistant strains [1,13–16]. Not
surprisingly, therefore, the development of new
antibacterial compounds to combat Gram-posit-
ive infections continues to be a prime area of drug
research. Indeed, several compounds are in
development, including ceftobiprole, dalbavan-
cin, daptomycin, oritavancin, telavancin and
tigecycline. However, many developmental anti-
biotics are based on existing classes of antimicro-
bial agents, and therefore raises concern, at least
theoretically, that antibiotic resistance will devel-
op quickly, notably through cross-resistance with
existing agents.
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Daptomycin is the first of a novel group of
compounds classified as the cyclic lipopeptides.
This article will review the mechanism of action
of daptomycin, and its pharmacokinetics, efficacy
against Gram-positive bacteria (particularly sta-
phylococci) and potential for leading to the
development of resistance. Clinical trial efficacy
and safety data will also be presented to assess
the potential role of daptomycin as a treatment
against Gram-positive pathogens.
DEVELOPMENT OF DAPTOMYCIN
Daptomycin was first isolated from Streptomyces
roseosporus through a soil-screening programme,
and clinical development by Eli Lilly began in
1985. The initial development programme was
terminated with the occurrence of potential drug-
induced myopathic events in two subjects during
phase I clinical trials. Over time, however, as
understanding of the occurrence, effects and
management of drug-induced myopathies
increased, and as the need for new antibiot-
ics—particularly those with activity against
MRSA—became more pressing, the potential
clinical utility of daptomycin was re-evaluated.
Cubist Pharmaceuticals Inc. licensed daptomycin
from Lilly in 1997 and re-instigated clinical
development using a refined once-daily dosing
regimen, with the aim of retaining antimicrobial
efficacy while minimising potential toxicity. Chir-
on BioPharmaceuticals, under licence from Cub-
ist, is developing the drug in Europe and various
other regions, excluding the USA. Daptomycin
has been in clinical use in the USA since 2003 for
the treatment of Gram-positive complicated skin
and skin structure infections (cSSSIs), and Euro-
pean approval of its use for Gram-positive com-
plicated skin and soft tissue infections is expected
in early 2006.
MECHANISM OF ACTION
Daptomycin has a mode of action unlike that of
any other available antibiotic to date [17]. It is a
13-membered amino-acid cyclic lipopeptide with
a hydrophilic core and hydrophobic tail [17]. The
hydrophobic tail of daptomycin binds irreversibly
to the cell membrane of Gram-positive bacteria
via a calcium-dependent process [17–19]. A chan-
nel is formed, causing rapid depolarisation of the
cell membrane due to efflux of potassium, and
possibly other cytoplasmic ions [17]. Bacterial cell
death results from the widespread dysfunction of
macromolecular synthesis [17,19]. Unlike b-lac-
tam antibiotics, daptomycin does not depend on
cell lysis to kill the bacterial cell [19].
PHARMACOKINETICS
Daptomycin has a relatively long half-life of
8–9 h, thereby making it suitable for once-daily
dosing [20]. It exhibits consistent and predictable
kinetics for doses of 4, 6 and 8 mg ⁄ kg per day
(maximum concentration (Cmax) of 58, 99 and
133 mg ⁄L, 24-h area under the curve (AUC) of
494, 747 and 1130 mg ⁄ h per litre, respectively)
[20]. Its low volume of distribution (0.1 L ⁄ kg)
indicates that it remains primarily within plasma
and interstitial fluid [20]. Daptomycin is excreted
mainly in urine (78%), with approximately 50%
of the active drug being recovered unchanged
from urine within 24 h [20,21]. A small proportion
of daptomycin (6%) is also recovered in faeces.
Daptomycin exhibits approximately 92% bind-
ing to plasma proteins, especially albumin. How-
ever, its binding to plasma proteins appears to be
weaker than the irreversible bond it forms with
the bacterial membrane, resulting in daptomycin
being significantly more bioavailable than this
level of protein binding would suggest [22].
Indeed, one study, presented at the 42nd Infec-
tious Diseases Society of America Annual Meet-
ing, 30 September – 3 October 2004, demonstrated
that the extent of increase in MICs of daptomycin
in 5% albumin and 95% human and mouse sera
was less than would be expected from its level of
protein binding (abstract 302). Another study,
presented at the 45th Interscience Conference on
Antimicrobial Agents and Chemotherapy, Wash-
ington, DC (16–19 December 2005), reported only
4.44- to 5.33-fold increases in MIC of daptomycin
in the presence of 4% human albumin, 50%
human serum or 100% mouse serum (abstract
D-1644). These data suggest that daptomycin is
two- to four-fold more active than predicted from
its free unbound drug concentrations.
AUC ⁄MIC or Cmax ⁄MIC pharmacodynamic
ratios best correlate with in-vivo efficacy against
standard strains of S. aureus and Streptococcus
pneumoniae [23]. Given the fact that daptomycin
neither inhibits nor stimulates cytochrome P450
enzymes [21,24], and that there are currently no
known drug–drug interactions, daptomycin may
Rybak Efficacy and safety of daptomycin 25
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12 (Suppl. 1), 24–32
be used in combination with a range of other
therapeutic agents.
IN-VITRO EFFICACY
Daptomycin has demonstrated broad efficacy
against Gram-positive pathogens, including sus-
ceptible and multidrug-resistant staphylococci
and enterococci. Its activity has been compared
in vitro with those of vancomycin, linezolid and
quinupristin–dalfopristin for a range of Gram-
positive bacterial strains (n ¼ 203), including
MRSA, vancomycin-resistant enterococci and
vancomycin-intermediate S. aureus [25,26]. The
MICs at which 90% of strains were inhibited are
shown in Table 1. Overall, daptomycin was more
active against all organisms tested except Entero-
coccus faecium, against which its activity was
similar to that of quinupristin–dalfopristin. Other
studies showed that daptomycin is active against
most of the clinical isolates tested, with
MICs between 0.006 and 2.0 mg ⁄L [27–32]. Fur-
thermore, in a worldwide surveillance study,
daptomycin was shown to be active against all
strains of vancomycin-resistant E. faecium
(MIC90 4 mg ⁄L) [33].
Notably, daptomycin is also active in vitro
against the recently isolated Michigan and Penn-
sylvania (Hershey) strains of vancomycin-resist-
ant S. aureus (MICs of 1.0 and 0.5 mg ⁄L,
respectively) [10,27,34].
BACTERICIDAL ACTIVITY
Daptomycin is rapidly bactericidal in vitro [17]. In
time-kill studies, at a concentration of four times
the MIC, daptomycin achieved 99.9% killing of
MRSA in 8 h, which was greater than the kill rates
for either linezolid or quinupristin–dalfopristin
(p < 0.05) [25]. In a comparison of four antibiotics,
daptomycin, at a concentration of 2 mg ⁄L (the
tentative breakpoint at the time of the study),
resulted in bactericidal activity against 92% of
strains tested (108 staphylococcal isolates, inclu-
ding MRSA and vancomycin-intermediate
S. aureus) [35]; the other rates found were 72%
for vancomycin, 46% for quinupristin–dalfopris-
tin and 7% for linezolid at their respective
breakpoint concentrations.
Sequestered high-bacterial-density infections,
such as those found in patients with endocarditis
and osteomyelitis, are often difficult to treat.
Antibiotic failure may occur because of poor drug
penetration, inoculum effects, high degree of
protein binding, and the presence of stationary-
phase organisms—a likely consequence of nutri-
ent limitations at the seat of the infection [17,36].
In a comparison of daptomycin, nafcillin, linezo-
lid and vancomycin, the activities of the antibiot-
ics were investigated alone, and in combination
with gentamicin, against high (9.5 log10 CFU ⁄ g)
and moderate (5.5 log10 CFU ⁄ g) inocula of meth-
icillin-susceptible S. aureus (MSSA) and MRSA
over 72 h in an in-vitro pharmacodynamic model
simulating endocardial vegetations [36]. Human
therapeutic dosing regimens of each drug were
simulated. Comparable bactericidal activities
(99.9% kill) were seen for nafcillin (MSSA only),
vancomycin and daptomycin against a moderate
inocolum, with a more rapid onset of activity for
daptomycin and nafcillin than for vancomycin (4
vs. 32 h, respectively (Fig. 1). At a high inoculum,
Table 1. Activities of daptomycin
and other antibiotics against various
bacterial strains in vitro [25]
Bacteria
(no. of isolates)
MIC90 mg ⁄L
Daptomycin Vancomycin Linezolid
Quinopristin–
dalfopristin
MSSA (50) 0.13 1.0 4.0 1.0
MRSA (50) 0.13 1.0 4.0 1.0
MSSE (25) 0.50 1.0 4.0 0.50
MRSE (25) 0.25 1.0 4.0 0.25
Enterococcus faecalis (25)a 1.0 64.0 4.0 16.0
Enterococcus faecium (25)a 4.0 64.0 4.0 4.0
MIC90, minimum inhibitory concentration at which 90% of strains are inhibited;
MRSA, methicillin-resistant Staphylococcus aureus; MRSE, methicillin-resistant
Staphylococcus epidermidis; MSSA, methicillin-susceptible Staphylococcus epider-
midis; MSSE, methicillin-susceptible Staphylococcus epidermidis.
aIncludes vancomycin-resistant enterococci.
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daptomycin demonstrated bactericidal activity
against both MSSA and MRSA by 24 h, whereas
vancomycin, linezolid (against both MSSA and
MRSA) and nafcillin (against MSSA alone) did
not achieve bactericidal activity throughout the
entire 72-h study period (Fig. 2). The addition of
gentamicin increased the rate of bactericidal
activity of daptomycin to 8 h and that of nafcillin
to 48 h, but had no effect on the rates of kill for
either vancomycin or linezolid over the duration
of the experiment. Furthermore, daptomycin’s
bactericidal activity, unlike most other agents,
has been shown to be maintained in the stationary
phase, which may be an important factor in the
treatment of deep-seated infections [37].
The bactericidal effects of daptomycin have
also been demonstrated using minimum bacteri-
cidal concentration ⁄MIC ratio determination. Ry-
bak et al. tested 103 S. aureus isolates (50 MRSA,
50 MSSA and three glycopeptide-intermediate
S. aureus) and 50 Staphylococcus epidermidis isolates
(25 methicillin-susceptible S. epidermidis and 25
methicillin-resistant S. epidermidis) and demon-
strated the bactericidal activity of daptomycin
(i.e., minimum bactericidal concentration within
two dilutions of MIC) to be superior to that of
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Fig. 1. In-vitro bactericidal activity
of daptomycin, linezolid and
vancomycin against a moderate
inoculum of methicillin-resistant
Staphylococcus aureus [36].
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Fig. 2. In-vitro bactericidal
activity of daptomycin, linezolid,
vancomycin and gentamicin
(alone and in combination)
against a high inoculum of
methicillin-resistant Staphylococ-
cus aureus [36].
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vancomycin, linezolid or quinupristin–dalfopris-
tin [25]. The minimum bactericidal concentra-
tion ⁄MIC ratios of daptomycin for 17 E. faecium
isolates (vancomycin-resistant) were determined
by Snydman et al. [38]. Daptomycin was bacteri-
cidal for 82% (14 ⁄ 17) of the strains.
SYNERGY STUDIES AND
POST-ANTIBIOTIC EFFECT
The activity of daptomycin has also been inves-
tigated in combination with other antibiotics,
most commonly against Enterococcus spp. Synergy
was observed against 13 of 18 vancomycin-resist-
ant enterococcal isolates treated with daptomycin
plus rifampin using an agar Etest screening
method; a later time-kill study supported these
results [39]. Additive or synergistic effects have
also been demonstrated with daptomycin plus
ampicillin against Enterococcus faecalis and E. fae-
cium isolates as well as daptomycin plus gentam-
icin against an ampicillin-resistant E. faecium
isolate [40]. Antagonism between daptomycin
and other antibiotics has not been seen.
Daptomycin has a long-lasting post-antibiotic
effect, which is concentration-dependent and lasts
up to 6 h against S. aureus and E. faecalis in the
presence of free calcium at physiological concen-
trations [41].
DEVELOPMENT OF RESISTANCE TO
DAPTOMYCIN
History has shown that whenever a new antibiotic
is introduced into widespread use, clinically
significant resistance eventually appears. In-vitro
studies have shown, to date, that it is difficult to
generate daptomycin-resistant isolates. Daptomy-
cin’s unique mechanism of action targets the
bacterial cell wall, and this is typically associated
with a relatively slow rate of inheriting resistance
compared with, for example, rRNA [17]. In-vitro
experiments testing for the emergence of sponta-
neous resistance to daptomycin demonstrated
that no spontaneous resistant mutants were
obtained for any of the bacteria tested: < 10)10
for S. aureus, < 10)9 for S. epidermidis, E. faecalis or
E. faecium, and < 10)8 for S. pneumoniae [42].
Furthermore, over 20 passages in the presence of
daptomycin were required to generate a modest
number of isolates with reduced susceptibility to
daptomycin. Stable S. aureus mutants could be
generated by both serial passage in liquid media
(one isolate in 27 days) and chemical mutagenesis
(11 isolates), but these mutants had only modest
(eight- to 32-fold) increases in daptomycin MICs
compared with the parental strain [42]. Consistent
with these in-vitro findings, the emergence of
daptomycin resistance during clinical use
has been rare, with only three instances in
E. faecium (MIC > 32 mg ⁄L), one in E. faecalis
(MIC 16 mg ⁄L) and five in S. aureus (MIC 2–
8 mg ⁄L) reported to date (45th Interscience
Conference on Antimicrobial Agents and Chemo-
therapy, 16–19 December 2005, abstract L-2141;
Infectious Disease Society of America 2005
Annual Meeting, 6–9 October 2005, abstract 490
[43–48]).
None of the daptomycin-resistant mutants gen-
erated in vitro have demonstrated resistance to
vancomycin or ampicillin, which is consistent
with the differences in the mechanisms of action
of these drugs [42]. The development of cross-
resistance between daptomycin and glycopeptide
or b-lactam antibiotics appears unlikely because
of daptomycin’s unique mechanism of action [49].
The problem of cross-resistance is common with
many other antibiotics because they have been
developed by making modifications to existing
classes of antibiotics [49].
CLINICAL STUDIES
COMPLICATED SKIN AND SOFT TISSUE
INFECTIONS
Food and Drug Administration approval for the
use of daptomycin to treat Gram-positive cSSSIs
in the USA was obtained, based on the results
yielded by two pivotal clinical studies. Each
randomised, evaluator-blinded phase III study
involved approximately 500 patients (total popu-
lation 1092 patients, aged 18–85 years). Patients
presented with cSSSIs, associated or potentially
associated with Gram-positive bacteria, including
abscesses, surgical and traumatic wound infec-
tions and infected diabetic foot ulcers [50]. Dap-
tomycin 4 mg ⁄ kg intravenously once-daily,
administered as a 30-min infusion, was compared
with vancomycin 1 g intravenously twice-daily,
given as a 60-min infusion, or an oxacillin-class
antibiotic (cloxacillin, flucloxacillin, oxacillin or
nafcillin) 4–12 g intravenously once-daily, for
7–14 days. The primary objective of the study
28 Clinical Microbiology and Infection, Volume 12 Supplement 1, 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12 (Suppl. 1), 24–32
was to demonstrate that daptomycin was not
inferior to the comparator agents. Non-inferiority
was defined as an upper boundary of 95% CI of
less than 10% (as recommended by the Division
of Anti-Infective Drug Products of the US Food
and Drug Administration).
Both trials (individually and collectively) met
the clinical and statistical criteria for demonstra-
ting non-inferiority of daptomycin to comparator
antibiotic treatment; results were consistent across
all predefined patient populations, different
species of Gram-positive bacteria, all types of
infection and post-treatment relapse rates [50].
For the combined intention-to-treat population
(n ¼ 1092), clinical success rates were 71.5% and
71.1% (95% CI )5.8 to 5.0) for daptomycin- and
comparator-treated patients, respectively. Equiv-
alent rates in the clinically evaluable population
were 83.4% and 84.2%, respectively. The clinical
success rates, broken down by infecting Gram-
positive organism for the microbiologically eval-
uable population, are shown in Table 2, and also
demonstrate that treatment with daptomycin was
not inferior to treatment with the comparator
antibiotics. An interesting finding of this study
was the shorter duration of treatment required
with daptomycin than with comparator antibiot-
ics, as decided by the study investigators
(Table 3) [50].
Other clinical trials
Daptomycin is currently indicated in the USA for
the treatment of cSSSIs caused by strains of
Staph. aureus (including MRSA), Streptococcus
pyogenes, Streptococcus agalactiae, Streptococcus dys-
galactiae equisimilis and E. faecalis (vancomycin-
susceptible isolates only). In Europe, daptomycin
is currently being reviewed by the European
Medicines Evaluation Agency for the treatment of
Gram-positive complicated skin and soft tissue
infections. Daptomycin is also being investigated
for other conditions. A recently completed inter-
national, multicentre, prospective, randomised,
controlled, open-label phase III trial evaluated
daptomycin in patients with S. aureus endocardi-
tis or bacteraemia [17]. Patients with bacteraemia
(MSSA or MRSA) were randomised for 2–6 weeks
of treatment with intravenous daptomycin,
6 mg ⁄ kg daily, or a semi-synthetic intravenous
penicillin, 2 g ⁄ 6-times-daily, or intravenous
vancomycin, at standard doses twice-daily,
according to susceptibility. MRSA was isolated
from 37% and 38% of patients in the daptomycin
and comparator arms, respectively. Patients in the
comparator arm of the study received an initial
4 days of treatment with intravenous gentamicin,
and all patients were followed up for 12 weeks.
The primary endpoint of non-inferiority was met
in both the intention-to-treat (n ¼ 235) and per-
protocol (n ¼ 139) populations. The most
common adverse events in both the daptomycin
Table 2. Clinical success rates for
daptomycin and comparator treat-
ment for complicated skin and skin
structure infections, broken down
by infecting Gram-positive organ-
ism for the microbiologically evalu-
able population [50]
Infective organism Daptomycin Comparatora 95% CI
Staphylococcus aureusb
Methicillin-susceptible 170 ⁄ 198 (85.9%) 180 ⁄ 207 (87.0%) ) 5.6 to 7.8
Methicillin-resistant 21 ⁄ 28 (75.0%) 25 ⁄ 36 (69.4%) ) 28.5 to 17.4
Streptococcus pyogenes 79 ⁄ 84 (94.0%) 80 ⁄ 88 (90.9%) ) 11.1 to 4.9
Streptococcus agalactiae 23 ⁄ 27 (85.2%) 22 ⁄ 29 (75.9%) ) 30.9 to 12.2
Streptococcus dysgalactiae 8 ⁄ 8 (100%) 9 ⁄ 11 (81.8%) ) 48.6 to 12.2
Enterococcus faecalis 27 ⁄ 37 (73.0%) 40 ⁄ 53 (75.5%) ) 16.3 to 21.3
aCloxacillin, flucloxacillin, nafcillin, oxacillin or vancomycin.
bMethicillin susceptibility was determined only for isolates received by the
central microbiology laboratories.
Table 3. Duration of intravenous antibiotic therapy in
patients successfully treated with intravenous daptomycin
or comparator antibiotic for complicated skin and skin
structure infections. Groups comprise those patients from
the clinically evaluable (CE) population who were consid-
ered as clinical successes and who did not receive oral
antibiotics [50]
Duration
of
treatment
Daptomycin
(n = 372; 83.4%
of CE)
Comparatora
(n = 384; 84.2%
of CE)
4–7 days 63% 33%
‡ 8 days 37% 67%
CE, clinically evaluable.
aCloxacillin, flucloxacillin, nafcillin, oxacillin or vancomy-
cin.
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and comparator arms included musculo-skeletal
symptoms, nausea, vomiting and oedema. These
data were presented as a late-breaker session at
the Interscience Conference on Antimicrobial
Agents and Chemotherapy, 16–19 December
2005, abstract K-426a.
The efficacy of daptomycin for the treatment of
community-acquired pneumonia was investi-
gated in two international phase III clinical trials
including almost 1000 patients (Cubist Pharma-
ceuticals, data on file; reported by LaPlante and
Rybak [51]). The primary objective was to dem-
onstrate non-inferiority in clinical efficacy
(defined as resolution of signs and symptoms) of
intravenous daptomycin 4 mg ⁄ kg per day com-
pared to standard therapy (intravenous ceftriax-
one 2 g ⁄day). However, the primary endpoint
was not met, possibly as a consequence of the
significant reduction in activity of daptomycin in
the presence of pulmonary surfactant [52]. Dap-
tomycin is therefore not indicated for the treat-
ment of pneumonia [21].
SAFETY AND TOLERABILITY
In the two pivotal phase III efficacy trials for cSSSIs,
daptomycin was well-tolerated, with the fre-
quency and distribution of adverse events (AEs)
being similar for patients receiving daptomycin
(n ¼ 534) and those given comparator antibiotics
(n ¼ 558) [50]. Most AEs were considered to be
unrelated to study medication and were of mild-
to-moderate intensity. One or more drug-related
AEs occurred in 18% of daptomycin-treated
patients and in 21% of patients treated with
comparator agents [50]. The most frequently
experienced AEs were gastrointestinal distur-
bances, injection site reactions and headache, at
frequencies comparable to or lower than those seen
with comparator antibiotics [50]. A total of 2.8% of
patients from each group discontinued treatment.
Given the potential for daptomycin-related
muscle toxicity as reported in the early phase
trials of daptomycin that employed multiple daily
dosing, creatine phosphokinase (CPK) levels were
closely monitored throughout the studies. The
distribution of CPK values was comparable across
treatment groups at baseline, as well as during
and after treatment [50]. In the phase III cSSSI
trials, elevations in CPK levels were reported in
9.3% of daptomycin recipients and 8.9% of
patients treated with the comparator drug [53].
Only two (0.2%) patients treated with daptomy-
cin experienced CPK elevations associated with
myalgia and ⁄ or muscle weakness. In both these
cases, clinical symptoms as well as laboratory
abnormalities resolved after discontinuation of
treatment with daptomycin.
CONCLUSIONS
Daptomycin is the first member of a novel class of
antibiotics, the cyclic lipopeptides. It has a rapid
onset and broad spectrum of bactericidal activity
against Gram-positive pathogens, including
MRSA, vancomycin-intermediate S. aureus, vanco-
mycin-resistant S. aureus and vancomycin-resist-
ant enterococcal isolates. It is highly active against
both growing and stationary-phase bacteria. In
clinical trials, daptomycin demonstrated a favour-
able safety profile and efficacy comparable to that
of standard therapy in the treatment of cSSSIs.
Because of its unique mode of action, daptomycin
has a low propensity to result in the development
of resistant bacteria.
Daptomycin was introduced into clinical prac-
tice in the USA in 2003 and is currently indicated
for the treatment of cSSSIs; it is expected to be
available in Europe early in 2006. Results from
recently completed and ongoing studies will
establish the spectrum of clinical utility of dapto-
mycin as a potential alternative to current agents,
notably the glycopeptides, for the treatment of
other Gram-positive bacterial infections.
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